^
Association details:
| Biomarker: | PIM1 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
Published date:
02/09/2022
Excerpt:
The CDP (including CD79B and/or PIM1mutations) group was identified in 27 cases (67.5%), and the non-CDP (without CD79B and PIM1 mutations) group was identified in 13 cases 32.5%). The CDP group tended to occur in older patients (median age 57.0 vs. 48.4 years, p=0.015). Patients in the CDP group had a significantly longer 2-year overall survival (OS) (76% and 40%, p=0.0372) than those in the non-CDP group...Patients with PIM1 and/or CD79B mutations had favorable long-term survival after high-dose methotrexate-based polychemotherapy.
DOI:
10.3389/fonc.2022.824632
